S

Shandong Boan Biotechnology Co Ltd
HKEX:6955

Watchlist Manager
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Watchlist
Price: 8.08 HKD -5.94% Market Closed
Market Cap: 4.3B HKD
Have any thoughts about
Shandong Boan Biotechnology Co Ltd?
Write Note

Shandong Boan Biotechnology Co Ltd
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shandong Boan Biotechnology Co Ltd
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Retained Earnings
-ÂĄ520.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Retained Earnings
-ÂĄ57.7B
CAGR 3-Years
-28%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Retained Earnings
ÂĄ8.2B
CAGR 3-Years
70%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Retained Earnings
ÂĄ10.2B
CAGR 3-Years
23%
CAGR 5-Years
26%
CAGR 10-Years
32%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Retained Earnings
ÂĄ29.1B
CAGR 3-Years
35%
CAGR 5-Years
61%
CAGR 10-Years
48%
Imeik Technology Development Co Ltd
SZSE:300896
Retained Earnings
ÂĄ3.1B
CAGR 3-Years
56%
CAGR 5-Years
84%
CAGR 10-Years
N/A
No Stocks Found

Shandong Boan Biotechnology Co Ltd
Glance View

Market Cap
4.1B HKD
Industry
Biotechnology

Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong and currently employs 631 full-time employees. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.

Intrinsic Value
12.91 HKD
Undervaluation 37%
Intrinsic Value
Price
S

See Also

What is Shandong Boan Biotechnology Co Ltd's Retained Earnings?
Retained Earnings
-520.7m CNY

Based on the financial report for Dec 31, 2023, Shandong Boan Biotechnology Co Ltd's Retained Earnings amounts to -520.7m CNY.

What is Shandong Boan Biotechnology Co Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 1Y
-23%

Over the last year, the Retained Earnings growth was -23%.

Back to Top